VEGF Corautus Genetics (MM)

ATLANTA, Nov. 7 /PRNewswire-FirstCall/ -- Corautus Genetics Inc. (NASDAQ:VEGF), a development stage company dedicated to the development of innovative therapy products in the life sciences industry, will release its third quarter 2006 financial results on Tuesday, November 14, 2006. Corautus will also host a conference call to discuss the results and provide an update of its therapeutic development program at 10:00 A.M. Eastern time on November 14. Richard Otto, President and Chief Executive Officer of Corautus, will host the call. To access the live webcast, please log on to the Corautus' website at http://www.corautus.com/ and go to the Investor Relations section. Alternatively, domestic callers may participate in the conference call by dialing (866) 356-3095, and international callers may participate in the conference call by dialing (617) 597-5391. The participant passcode for access to the conference is "Corautus". Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call. Domestic callers can access the replay by dialing (888) 286-8010, and international callers can access the replay by dialing (617) 801-6888; the PIN access number is 20060446. Forward-Looking Statements This press release may contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain factors, risks and uncertainties that may cause actual results, events and performances to differ materially from those referred to in such statements. These risks include statements that address operating performance, events or developments that we expect or anticipate will occur in the future, such as the likelihood of identifying and securing life sciences opportunities upon which to focus our resources and the adequacy of our cash position to transition to new opportunities if found, future results of operations or our financial condition, adequacy of funding, benefits from the alliance with Boston Scientific, research, development and commercialization of any product candidates, anticipated trends in our business, approval of our product candidates, meeting additional capital requirements, and other risks that could cause actual results to differ materially. These risks are discussed in Corautus Genetics Inc.'s Securities and Exchange Commission filings, including, but not limited to, the risk factors in Corautus' 2005 Annual Report on Form 10-K which was filed on March 20, 2006 amended by Corautus' Form 10-Q for the period ended March 31, 2006 which was filed on May 15, 2006. All forward-looking statements included in this document are based on information available to Corautus on the date hereof, and Corautus assumes no obligation to update any such forward-looking statements. CONTACT: Corautus Genetics Inc. Michael K. Steele (404) 526-6212 DATASOURCE: Corautus Genetics Inc. CONTACT: Michael K. Steele of Corautus Genetics Inc., +1-404-526-6212, or Web site: http://www.corautus.com/

Copyright